Mutations of the TET2 and CBL genes: novel molecular markers in myeloid malignancies.
Standard
Mutations of the TET2 and CBL genes: novel molecular markers in myeloid malignancies. / Bacher, Ulrike; Haferlach, Claudia; Schnittger, Susanne; Kohlmann, Alexander; Kern, Wolfgang; Haferlach, Torsten.
in: ANN HEMATOL, Jahrgang 89, Nr. 7, 7, 2010, S. 643-652.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Mutations of the TET2 and CBL genes: novel molecular markers in myeloid malignancies.
AU - Bacher, Ulrike
AU - Haferlach, Claudia
AU - Schnittger, Susanne
AU - Kohlmann, Alexander
AU - Kern, Wolfgang
AU - Haferlach, Torsten
PY - 2010
Y1 - 2010
N2 - Despite recent progress in molecular research in myeloid malignancies, in subsets of patients with myelodysplastic syndrome (MDS) so far no underlying mutation was identified. In the myeloproliferative neoplasms (MPNs), the JAK2V617F alone cannot explain the phenotypic heterogeneity. In acute myeloid leukemia (AML), clinical variability exists within distinct subgroups. Thus, the search for novel molecular markers continues. Recently, mutations of the tet oncogene family member 2 (TET2) and Casitas B-cell lymphoma (CBL) genes became the focus of interest. With diverse genetic methods, TET2 on chromosome 4q24 was identified as candidate tumor suppressor gene. Sequencing studies revealed heterogeneous mutations in 10-25% of patients with acute myeloid leukemia (AML), MDS, and MPNs, while the frequency might be higher in chronic myelomonocytic leukemia (CMML). The prognostic impact is being explored. The CBL gene is involved in the degradation of tyrosine kinases. In rare cases of human AML (
AB - Despite recent progress in molecular research in myeloid malignancies, in subsets of patients with myelodysplastic syndrome (MDS) so far no underlying mutation was identified. In the myeloproliferative neoplasms (MPNs), the JAK2V617F alone cannot explain the phenotypic heterogeneity. In acute myeloid leukemia (AML), clinical variability exists within distinct subgroups. Thus, the search for novel molecular markers continues. Recently, mutations of the tet oncogene family member 2 (TET2) and Casitas B-cell lymphoma (CBL) genes became the focus of interest. With diverse genetic methods, TET2 on chromosome 4q24 was identified as candidate tumor suppressor gene. Sequencing studies revealed heterogeneous mutations in 10-25% of patients with acute myeloid leukemia (AML), MDS, and MPNs, while the frequency might be higher in chronic myelomonocytic leukemia (CMML). The prognostic impact is being explored. The CBL gene is involved in the degradation of tyrosine kinases. In rare cases of human AML (
M3 - SCORING: Zeitschriftenaufsatz
VL - 89
SP - 643
EP - 652
JO - ANN HEMATOL
JF - ANN HEMATOL
SN - 0939-5555
IS - 7
M1 - 7
ER -
